Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Coronary Artery Disease and Renal Failure Registry (CAD-REF)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2012 by Institut für Klinisch-Kardiovaskuläre Forschung GmbH.
Recruitment status was:  Active, not recruiting
BMBf (Federal Ministry of Education and Research)
KfH Kuratorium für Dialyse und Nierentransplantation e.V.
Boehringer Ingelheim
Sanofi-Aventis Deutschland GmbH
Information provided by:
Institut für Klinisch-Kardiovaskuläre Forschung GmbH Identifier:
First received: May 14, 2008
Last updated: November 1, 2012
Last verified: October 2012

It is the aim of the multi-centric and prospective registry to analyze in patients with CAD the impact of different grades of renal failure on the outcome and course of the patients and to correlate these with clinical variables.

In particular, the registry has the following objectives:

  • prospective consecutive assessment of all patients with coronary artery disease and renal failure in the participating hospitals of the registry
  • evaluation of the outcome and course of patients with regard to their different stages of renal failure at baseline
  • analysis of the impact of different therapeutic strategies on acute and long-term outcomes
  • identification of clinical risk factors, novel biomarkers and genetic markers for an unfavorable long-term outcome

Coronary Artery Disease
Renal Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Coronary Artery Disease and Renal Failure Registry

Resource links provided by NLM:

Further study details as provided by Institut für Klinisch-Kardiovaskuläre Forschung GmbH:

Primary Outcome Measures:
  • all cause mortality [ Time Frame: two years ]

Secondary Outcome Measures:
  • manner of death [ Time Frame: two years ]
    cardiac death; non-cardiac death; death of unknown cause

Other Outcome Measures:
  • Interventions [ Time Frame: two years ]
    Myocardial infarction or stroke; Renal failure or contrast medium induced nephropathy

Biospecimen Description:
Urine, whole blood, serum

Estimated Enrollment: 3352
Study Start Date: December 2007
Estimated Study Completion Date: May 2013
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Group 0 (Controllgroup)
eGFR >= 90 ml/min/1.73m^2 and no proteinuria
Group 1
eGFR >= 90 ml/min/1.73m^2 and proteinuria
Group 2
eGFR 60 - 89 ml/min/1.73m^2
Group 3
eGFR 30 - 59 ml/min/1.73m^2
Group 4
eGFR 15 - 29 ml/min/1.73m^2
Group 5
eGFR < 15 ml/min/1.73m^2 or requiring dialysis


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with diagnosed coronary artery disease were consecutively enrolled and classified into six groups according to their kidney function

Inclusion Criteria:

  • Women and men >= 18 years of age
  • Patients with actually performed interventional coronary angiography and there a documented coronary heart disease, defined as at least one documented stenosis >= 50 % in at least one main coronary vessel (Main steam; RCX; RIVA; RCA)
  • European/Caucasian descent (European/Caucasian parents and grandparents)
  • Availability of an urine, serum- and EDTA blood sample of the patient
  • Documented consent of patients for handling of personal medical data, including a genetic analysis

Exclusion Criteria:

  • Patients who have been already recruited into this registry
  • Patients with organ transplantations, apart from kidney transplantations
  • Immunosuppressive therapy, apart from immunosuppressive therapy after kidney transplantation
  • Patients with polycystic renal disease
  • Pregnant and breastfeeding patients
  • Known malignant tumor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00679419

Universitätsklinikum Aachen
Aachen, Germany
Zentralklinik Bad Berka
Bad Berka, Germany
Herz- und Gefäßklinik Bad Neustadt
Bad Neustadt, Germany
Bad Rothenfelde, Germany
Herzzentrum Brandenburg
Brandenburg, Germany
Coesfeld, Germany
Klinikum Lippe-Detmold
Detmold, Germany
Herzzentrum Duisburg
Duisburg, Germany
Evangelisches Krankenhaus Düsseldorf
Düsseldorf, Germany
Alfried Krupp Krankenhaus Essen
Essen, Germany
Klinikum Garmisch-Partenkirchen
Garmisch-Partenkirchen, Germany
Universitätsklinikum Halle/Saale
Halle/Saale, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Evangelisches Krankenhaus Hamm
Hamm, Germany
St. Marienhospital Hamm
Hamm, Germany
Medizinische Hochschule Hannover
Hannover, Germany
SLK-Kliniken Heilbronn GmbH
Heilbronn, Germany
Privatklinik Dr. Schindlbeck
Herrsching, Germany
Herzzentrum Lahr
Lahr, Germany
Kardiologische Praxis Dr. Schön
Mühldorf, Germany
Klinik Augustium München
München, Germany
Klinikum Neuperlach
München, Germany
Raphaelsklinik Münster
Münster, Germany
St. Franziskus-Hospital
Münster, Germany
Universitätsklinikum Münster
Münster, Germany
Lukaskrankenhaus Neuss
Neuss, Germany
Euregioclinic Nordhorn
Nordhorn, Germany
St. Vincenz-Krankenhaus
Paderborn, Germany
Klinikum Pirna
Pirna, Germany
Christliches Krankenhaus Quakenbrück e.V.
Quakenbrück, Germany
Zentralklinikum Suhl
Suhl, Germany
Josephs-Hospital Warendorf
Warendorf, Germany
Sponsors and Collaborators
Institut für Klinisch-Kardiovaskuläre Forschung GmbH
BMBf (Federal Ministry of Education and Research)
KfH Kuratorium für Dialyse und Nierentransplantation e.V.
Boehringer Ingelheim
Sanofi-Aventis Deutschland GmbH
Principal Investigator: Eva Brand, Prof. Dr. University Hospital of Muenster
Principal Investigator: Holger Reinecke, Prof. Dr. University Hospital of Muenster
Principal Investigator: Günter Breithardt, Prof. Dr. University Hospital of Muenster
Principal Investigator: Hermann Pavenstädt, Prof. Dr. University Hospital of Muenster
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00679419     History of Changes
Other Study ID Numbers: 1-071812
Study First Received: May 14, 2008
Last Updated: November 1, 2012

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Kidney Diseases
Urologic Diseases processed this record on May 25, 2017